domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md

@@ -113,6 +113,18 @@ Aon's temporal cost analysis shows medical costs rise 23% in year 1 but grow onl
 
 International generic competition beginning January 2026 (Canada patent expiry, immediate Sandoz/Apotex/Teva filings) creates price compression trajectory faster than 'inflationary through 2035' assumes. Oral Wegovy launched at $149-299/month (5-8x reduction vs $1,300/month injectable). China/India generics projected at $40-50/month by 2030. Aon 192K patient study shows break-even timing is highly price-sensitive: at $1,300/month, multi-year retention required; at $50-150/month, Aon data suggests cost savings within 12-18 months under capitation. The 'inflationary through 2035' conclusion holds at current US pricing but becomes invalid if international generic arbitrage and oral formulation competition compress effective prices to $50-150/month range by 2030. Scope qualification needed: claim is valid conditional on pricing trajectory assumptions that are now challenged by G7 patent cliff precedent.
 
+
+### Additional Evidence (challenge)
+*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-19*
+
+International generic competition beginning in 2026 creates price compression trajectory that contradicts the 'inflationary through 2035' conclusion. Canada's semaglutide patents expired January 4, 2026, with Sandoz, Apotex, and Teva filing immediately. Brazil opens to generics March 2026 (Biomm + Biocon). China has 17+ generic candidates in Phase 3 with projected pricing of $40-$50/month. India patents expire March 2026. Even with US patents extending to 2031-2032, international generic availability at $40-$50/month (95%+ below current US list price) creates arbitrage pressure that will compress US prices faster than the existing claim assumes. If global prices converge toward $50-100/month by 2030 (driven by international generics), the inflection point where volume growth no longer offsets price compression moves significantly earlier than 2035.
+
+
+### Additional Evidence (extend)
+*Source: [[2026-02-01-glp1-patent-cliff-generics-global-competition]] | Added: 2026-03-19*
+
+Oral Wegovy launched January 2026 at $149-$299/month (Medicare deal: $245/month), representing 50-75% reduction from injectable pricing. Orforglipron (Eli Lilly non-peptide small molecule) expected Q2 2026 approval. Amycretin shows 22% weight loss without plateau. The combination of oral formulations, next-generation compounds, and international generic competition creates a multi-vector price compression dynamic that accelerates the timeline for cost-effectiveness crossover.
+
 ---
 
 Relevant Notes:

inbox/queue/2026-02-01-glp1-patent-cliff-generics-global-competition.md

@@ -7,9 +7,13 @@ date: 2026-02-01
 domain: health
 secondary_domains: [internet-finance]
 format: article
-status: unprocessed
+status: enrichment
 priority: medium
 tags: [glp-1, generics, patent-cliff, global-competition, drug-pricing, market-structure]
+processed_by: vida
+processed_date: 2026-03-19
+enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -50,3 +54,15 @@ Overview of the GLP-1 generic competition landscape as patents begin expiring in
 PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]
 WHY ARCHIVED: Price trajectory is the key variable the existing claim depends on — if prices decline faster than assumed, the "inflationary through 2035" conclusion may be wrong
 EXTRACTION HINT: Focus on the price trajectory and its implications for cost-effectiveness under different payment models, especially the international competition pressure
+
+
+## Key Facts
+- Semaglutide patents extend to 2031-2032 in US and Europe
+- Canada's semaglutide patents expired January 4, 2026 — first G7 nation
+- Brazil generic competition opens March 2026
+- China has 17+ generic semaglutide candidates in Phase 3 trials
+- India semaglutide patents expire March 2026
+- Oral Wegovy launched January 2026 at $149-$299/month
+- Medicare negotiated oral Wegovy price: $245/month
+- Orforglipron (Eli Lilly) expected Q2 2026 approval
+- Amycretin shows 22% weight loss without plateau in trials